Search

Displaying results 7461 - 7470 of 10000 in total
  1. Drug

    Pentavalent Antimony

    go.drugbank.com/drugs/DB13047
    Investigational

    Pentavalent Antimony has been investigated for the treatment of Cutaneous Leishmaniasis.

  2. Drug

    VP-14637

    go.drugbank.com/drugs/DB12195
    Investigational

    MDT-637 has been investigated for the treatment of Drug Safety.

  3. Drug

    Tozadenant

    go.drugbank.com/drugs/DB12203
    Investigational

    Tozadenant has been investigated for the basic science of Cocaine Dependence.

  4. Drug

    Spiradoline

    go.drugbank.com/drugs/DB12704
    Investigational

    Spiradoline has been investigated for the basic science of Bipolar Depression.

  5. Drug

    CSIC002

    go.drugbank.com/drugs/DB18584
    Experimental

    CSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.

    Synonyms: NP-CSIC002
  6. Drug

    ENB-003

    go.drugbank.com/drugs/DB17340
    Investigational

    ENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.

  7. Drug

    FLT190

    go.drugbank.com/drugs/DB18420
    Investigational

    FLT190 is a recombinant adeno-associated viral vector serotype S3 containing DNA encoding for human alpha-galactosidase A.

  8. Drug

    AD 337

    go.drugbank.com/drugs/DB05725
    Investigational

    The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients. … AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia).

  9. Drug

    Penequinine, Penehyclidine

    go.drugbank.com/drugs/DB16287
    Investigational

    Penequinine, Penehyclidine is under investigation in clinical trial NCT02644876 (Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications).

  10. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]